Supportive Care and Medical Management
At a Glance
AARS2-related leukoencephalopathy has no established treatment that stops or reverses the disease. Care is individualized and focuses on hormone replacement for ovarian insufficiency when appropriate, rehabilitation, symptom relief, health monitoring, and coordinated specialists.
Because AARS2-related leukoencephalopathy is a complex condition affecting multiple systems, there is no established, disease-modifying cure. Instead, management is supportive and generally extrapolated from POI, leukodystrophy, and mitochondrial-disease guidance [1][2]. This means a team of specialists works together to manage your specific symptoms, prevent complications, and maintain your quality of life for as long as possible.
(Note: While researchers have studied supplements like alanine or “coenzyme complexes” in isolated cases, no supplement or mitochondrial cocktail has been proven to alter the course of AARS2-related disease. Patients should not start or stop treatments without their clinician’s advice [3][4].)
Managing Ovarian Insufficiency and Health Risks
For those affected by Premature Ovarian Insufficiency (POI), replacing missing hormones is a major part of care when not medically contraindicated.
- Hormone Replacement Therapy (HRT): General POI guidelines often recommend systemic estrogen replacement until around age 50 (the typical age of natural menopause) [5][6].
- The Goal: The aim is to manage symptoms of low estrogen and reduce long-term health risks. Transdermal patches (placed on the skin) may have a lower risk of blood clots than oral pills, but they are not risk-free [5][7]. The route and dose must be individualized for personal risks.
- Uterine Protection: If you still have your uterus, an added hormone called progestogen is necessary to protect the uterine lining from thickening [5][8].
- Bone and Heart Benefits: Replacing estrogen is important for preserving bone mineral density and managing cardiovascular risk factors [9][10]. Routine, individualized risk assessment (like DEXA scans and lipid checks) is crucial.
- Contraception: HRT does not reverse the brain disease, restore egg supply, or reliably prevent pregnancy. Because spontaneous ovulation can occasionally occur, contraception may be needed if pregnancy is not desired.
Neurological, Cardiac, and Physical Support
Neurological care focuses on “symptom-targeted” treatments to help you stay mobile and independent.
- Motor Symptoms: If you experience spasticity (stiffness) or dystonia (twisting movements), doctors may prescribe muscle relaxants or other movement-disorder medications [1].
- Physical and Occupational Therapy (PT/OT): Regular therapy is essential for managing ataxia (unsteadiness) and gait disturbances. Therapists can help with balance exercises and recommend assistive devices (like canes or braces) before they are urgently needed [1][11].
- Cardiac Evaluation: Because the broader AARS2 spectrum includes cardiomyopathy, ask whether baseline or follow-up cardiac assessment (like an EKG or echocardiogram) is appropriate [1].
- Seizure Management: If seizures occur, they must be managed with antiseizure medications [1].
Cognitive and Psychiatric Care
Because 86% of reported cases experienced cognitive changes and 70% faced psychiatric symptoms, mental health is a priority [1].
- Mood Management: Depression and anxiety are common and can be treated with standard therapies and medications.
- Cognitive Support: Working with a neuropsychologist can help you develop strategies to manage difficulties with memory, planning, and organization [1][12].
Building Your Care Team
Managing this condition requires a “home base” of specialists who communicate with one another:
- Neurologist: The lead for monitoring brain health, gait, and seizures.
- Reproductive Endocrinologist or Gynecologist: To manage HRT and monitor bone health [6][13].
- Cardiologist: To monitor heart health when relevant.
- Geneticist/Genetic Counselor: To provide guidance for family members and future planning [2].
- Psychiatrist or Psychologist: To support emotional well-being and treat behavioral changes [12].
- Rehabilitation Specialists: Including PT, OT, and sometimes speech-language pathologists for help with swallowing or communication [11].
Common questions in this guide
Is there a cure for AARS2-related leukoencephalopathy?
Could hormone replacement therapy help if I have ovarian insufficiency?
Does hormone replacement treat the brain disease or prevent pregnancy?
How are movement problems such as stiffness and unsteadiness treated?
What specialists should be involved in my care?
What health checks are important with AARS2-related leukoencephalopathy?
Can supplements change the course of AARS2-related disease?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on leukoencephalopathy, progressive, with ovarian failure.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my specific history, are there any contraindications (like blood clots or estrogen-sensitive cancers) that would prevent me from starting Hormone Replacement Therapy?
- 2.What is the target dose of estradiol for me, and should we use a transdermal patch or an oral tablet for safety?
- 3.If I have a uterus, which progestogen will we use to protect the uterine lining, and how often will my bleeding patterns be monitored?
- 4.Who will manage my routine bone-density, blood-pressure, lipid, and cardiac risk assessments?
- 5.Can you help coordinate my care between neurology, endocrinology, cardiology, and physical therapy to ensure we are all monitoring the same 'baseline'?
References
References (13)
- 1
The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature.
Wade C, de Paiva ARB, Nóbrega PR, et al.
Journal of neurology 2026; (273(7)).
PMID: 42362900 - 2
Primary mitochondrial diseases.
Pizzamiglio C, Hanna MG, Pitceathly RDS
Handbook of clinical neurology 2024; (204()):53-76 doi:10.1016/B978-0-323-99209-1.00004-1.
PMID: 39322395 - 3
Amino acid supplementation in patients affected by leukoencephalopathies associated with mitochondrial aminoacyl tRNA synthetase pathogenic variants: Pilot clinical trial in adults and review of literature.
Catania A, Marchet S, Einvag K, et al.
Molecular genetics and metabolism 2025; (146(3)):109259 doi:10.1016/j.ymgme.2025.109259.
PMID: 41075682 - 4
AARS2 leukoencephalopathy: A new variant of mitochondrial encephalomyopathy.
Tang Y, Qin Q, Xing Y, et al.
Molecular genetics & genomic medicine 2019; (7(4)):e00582 doi:10.1002/mgg3.582.
PMID: 30706699 - 5
Premature ovarian insufficiency: When ovaries retire early.
Sugianto SRS, Webber L, Safdar Husain F, et al.
Annals of the Academy of Medicine, Singapore 2025; (54(3)):178-191 doi:10.47102/annals-acadmedsg.2024227.
PMID: 40178424 - 6
The role of mitochondrial dysfunction and genetics in female infertility and premature ovarian insufficiency.
Kline BL, Compton AG, Frazier AE, et al.
Human reproduction update 2026; doi:10.1093/humupd/dmag022.
PMID: 42616676 - 7
Expert opinion by the Italian Society of Gynecology of the Third Age (SIGiTE) and the Italian Society of Menopause (SIM) on diagnosis and treatment of premature ovarian insufficiency.
Capozzi A, Ambroggio S, Cagnacci A, et al.
Minerva endocrinology 2026; (51(1)):88-95 doi:10.23736/S2724-6507.25.04422-7.
PMID: 41212137 - 8
Premature ovarian insufficiency - hormone replacement therapy and management of long-term consequences.
Machura P, Grymowicz M, Rudnicka E, et al.
Przeglad menopauzalny = Menopause review 2018; (17(3)):135-138 doi:10.5114/pm.2018.78559.
PMID: 30357030 - 9
Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis.
Gonçalves CR, Vasconcellos AS, Rodrigues TR, et al.
Reproductive biomedicine online 2022; (44(6)):1143-1157 doi:10.1016/j.rbmo.2022.02.006.
PMID: 35461762 - 10
Impact of hormone therapy on the bone density of women with premature ovarian insufficiency: A systematic review.
Costa GPO, Ferreira-Filho ES, Simoes RDS, et al.
Maturitas 2023; (167()):105-112 doi:10.1016/j.maturitas.2022.09.011.
PMID: 36368093 - 11
Pearls & Oy-sters: AARS2 Leukodystrophy-Tremor and Tribulations.
Green K, MacIver CL, Ebden S, et al.
Neurology 2024; (102(8)):e209296 doi:10.1212/WNL.0000000000209296.
PMID: 38507676 - 12
The emerging neurological spectrum of AARS2-associated disorders.
Parra SP, Heckers SH, Wilcox WR, et al.
Parkinsonism & related disorders 2021; (93()):50-54 doi:10.1016/j.parkreldis.2021.10.031.
PMID: 34784527 - 13
Premature ovarian failure.
Jankowska K
Przeglad menopauzalny = Menopause review 2017; (16(2)):51-56 doi:10.5114/pm.2017.68592.
PMID: 28721130
This page explains supportive care for AARS2-related leukoencephalopathy for informational purposes only and is not medical advice. Your neurology, reproductive-health, and other specialists should tailor hormone therapy, monitoring, and symptom treatment to your history.